FARXIGA is indicated:

  • to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression
  • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction
  • to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular (CV) disease or multiple CV risk factors
  • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; HFrEF=heart failure with reduced ejection fraction; hHF=hospitalization for heart failure; NYHA=New York Heart Association; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA